Oxford-AstraZeneca Covid’s Covid vaccine exhibits a mean effectiveness of 70% in stopping the virus

In this illustration dated September 9, 2020, a vaccine marked with a test tube can be seen in front of the AstraZeneca logo.

Given Ruvic | Reuters

LONDON – UK pharmaceutical company AstraZeneca said Monday that an interim clinical trial analysis showed its coronavirus vaccine had an average of 70% effectiveness in protecting against the virus.

It comes after a series of encouraging vaccination results in the past few weeks after Pfizer-BioNTech and Moderna read late-stage studies.

It is hoped that a Covid vaccine can help end the coronavirus pandemic that has killed more than 1.3 million people worldwide.

According to AstraZeneca, the vaccine, developed in partnership with Oxford University, was evaluated using two different dosing regimes.

One showed 90% effectiveness when subjects received half a dose followed by a full dose at least a month apart. The other dosage regimen showed 62% effectiveness when administered as two full doses at least one month apart.

The combined analysis of both dosage regimens showed an average vaccine effectiveness of 70%. No hospitalizations or serious illnesses were reported in the participants who received the vaccine.

In the interim analysis, a total of 131 Covid 19 cases were assessed.

Pascal Soriot, CEO of AstraZeneca, said the development was an “important milestone” in the fight against the global health crisis.

“The efficacy and safety of this vaccine confirm that it will be highly effective against COVID-19 and have an immediate impact on this public health emergency,” said Soriot.

“In addition, the vaccine’s simple supply chain and our charitable promise and commitment to widespread, equitable, and timely access means that it will be affordable, available worldwide, and deliver hundreds of millions of doses when approved.”

AstraZeneca said it would immediately prepare to submit the data to government agencies around the world that have a framework for conditional or early approval.

“These results show that we have an effective vaccine that will save many lives,” said Professor Andrew Pollard, chief investigator for the Oxford Vaccine Trial, in a statement.

“Excitingly, we’ve found that one of our dosing regimens can be about 90% effective. If that dosing regimen is used, more people could be vaccinated with the planned vaccine supply.”

This is breaking news, please try again later.

Comments are closed.